Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine, Carboplatin, Topotecan, and Thalidomide in Relapsed/Refractory AML, CML, and MDS
NCT00053287Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Sep 2002
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), sponsored by Case Comprehensive Cancer Center. Started Sep 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00053287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053287.